Back to Results
First PageMeta Content
Ancient Rome / V / Cohort / Military of ancient Rome


AbstFirst in human phase I study - results of a second-generation non-ansamycin Heat Shock Protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors Daruka Mahadevan1, Diane M. Rensvold1, Sandra E. Kurtin1,
Add to Reading List

Document Date: 2013-01-20 11:10:59

Open Document

File Size: 2,42 MB

Share Result on Facebook

City

Boston / Tucson / Cambridge / Dublin / /

Company

Astex Pharmaceuticals Inc. / Once Weekly / 3Astex Pharmaceuticals / /

Country

United States / United Kingdom / /

Facility

Farber Cancer Institute / Cancer Center / /

MedicalCondition

refractory solid tumors Daruka Mahadevan1 / /

Organization

2Dana Farber Cancer Institute / Geoffrey Shapiro2 1Arizona Cancer Center / /

SocialTag